Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹958 Cr
Revenue (TTM)
₹630 Cr
Net Profit (TTM)
₹39 Cr
ROE
11 %
ROCE
13.8 %
P/E Ratio
24.8
P/B Ratio
1.8
Industry P/E
42.17
EV/EBITDA
14
Div. Yield
1.5 %
Debt to Equity
0
Book Value
₹107.4
EPS
₹8
Face value
10
Shares outstanding
48,285,605
CFO
₹276.74 Cr
EBITDA
₹513.98 Cr
Net Profit
₹257.86 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kopran
| -6.7 | 5.5 | 24.8 | -17.3 | -4.6 | 43.0 | 15.7 |
|
BSE Healthcare
| -2.9 | 5.5 | 11.4 | 19.3 | 25.8 | 22.2 | 11.0 |
|
BSE Small Cap
| -2.8 | 9.3 | 20.7 | 6.0 | 27.2 | 35.1 | 17.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Kopran
| -15.7 | 59.9 | -53.4 | 133.2 | 344.6 | -19.8 | -43.1 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kopran
|
197.5 | 958.0 | 629.6 | 38.6 | 8.6 | 7.6 | 24.8 | 1.8 |
| 895.7 | 8,248.7 | 2,115.1 | 272.4 | 17.8 | 14.2 | 30.3 | 4.1 | |
| 1,097.6 | 9,000.7 | 1,006.9 | 160.4 | 20.4 | 12.6 | 56.7 | 6.9 | |
| 570.2 | 8,941.6 | 4,118.2 | 343.8 | 7.6 | 10.7 | 26.4 | 2.9 | |
| 372.3 | 4,629.3 | 1,859.8 | 90.8 | 10.4 | 7.4 | 51 | 3.7 | |
| 912.1 | 5,363.1 | 1,243.7 | 128.3 | 13.0 | 13.8 | 41.8 | 5.6 | |
| 1,001.1 | 2,469.2 | 356.3 | 100.9 | 25.0 | 13.3 | 24.5 | 3.1 | |
| 250.7 | 2,241.6 | 782.8 | 67.4 | 13.4 | 11.5 | 32.4 | 3.5 | |
| 166.3 | 5,364.3 | 71.8 | -342.5 | -467.5 | -- | -- | -24.7 | |
| 963.3 | 2,890.5 | 293.0 | -56.7 | -16.7 | -29.5 | -- | 9.3 |
No Review & Analysis are available.
Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms,... including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India. Read more
Incorporated
1958
Chairman
Susheel G Somani
Managing Director
--
Group
Parijat
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kopran Ltd stood at ₹ 844 Cr as on 31-Mar-25
The share price of Kopran Ltd is ₹197.52 (NSE) and ₹197.40 (BSE) as of 13-Jun-2025 12:39 IST. Kopran Ltd has given a return of -4.57% in the last 3 years.
Kopran Ltd has a market capitalisation of ₹ 958 Cr as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kopran Ltd is 1.85 times as on 13-Jun-2025, a 51% discount to its peers’ median range of 3.75 times.
The P/E ratio of Kopran Ltd is 24.85 times as on 13-Jun-2025, a 41% discount to its peers’ median range of 42.17 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kopran Ltd and enter the required number of quantities and click on buy to purchase the shares of Kopran Ltd.
Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
The prominent promoters of Kopran Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
ORICON ENTERPRISES LIMITED |
12.88%
|
|
PANORAMA FINVEST PVT LTD |
7.87%
|
|
SARVAMANGAL MERCANTILE CO LTD |
6.01%
|
|
UNITED SHIPPERS LTD |
4.56%
|
|
SURENDRA SOMANI |
3.65%
|
The chairman of the company is Susheel G Somani, and the managing director is .
There is no promoter pledging in Kopran Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,341
|
|
|
8,872
|
|
|
8,246
|
|
|
5,368
|
|
|
5,101
|
|
|
4,591
|
|
|
2,775
|
|
|
2,499
|
|
|
2,175
|
| Kopran Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
7.59
|
|
Operating margin(%)
|
8.61
|
|
Net Margin(%)
|
6.06
|
|
Dividend yield(%)
|
1.49
|
Yes, TTM profit after tax of Kopran Ltd was ₹39 Cr.
₹-3.93
(
